This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Your Vote Counts: Who Is the Worst Biotech CEO of 2011?

BOSTON ( TheStreet) -- A desperate, $11 billion Hail Mary acquisition, two botched drug launches, a clueless, tin-eared investor relations strategy, and an expensive and quixotic quest to develop a product no one needs -- these are the transgressions that have earned five executives the dishonor of being nominated for TheStreet's Worst Biotech CEO of 2011 Award.

You, the readers, (the 99%!) will decide which of these five nominees is the worst of the worst and deserves to hold aloft the Nance Trophy.

The five Worst Biotech CEO nominees for 2011 are John Martin of Gilead Sciences (GILD - Get Report), Mitch Gold, Dendreon (DNDN), Amarin's (AMRN - Get Report) Joseph Zakrzewski, Al Mann of Mannkind (MNKD) and Gregory Divis Jr. of K-V Pharmaceuticals (KV.A).

The Nance Trophy is named in recognition of David Nance, the former CEO of now bankrupt and defunct Introgen Therapeutics. Few CEOs in biotech did more to hone the fine craft of investor bamboozlement and outright incompetence as Introgen's Nance.

Past winners (or should I say losers?) of the Worst Biotech CEO of the Year Award are Elan's (ELN) Kelly Martin in 2008, Genzyme's Henri Termeer in 2009 and Dan Bradbury of Amylin Pharmaceuticals (AMLN) last year.

For the 2011 crowning, I'd like readers to cast the deciding votes. Read the following nominating summaries and make your selection in the interactive poll at the end of this story. Feel free also to post comments if you feel I left off a CEO deserving of shame. I'll tally the votes and award the trophy in a week.

John Martin, Gilead Sciences:

Honest to God truth, I wrote up Martin's nomination for worst biotech CEO on the Sunday afternoon before Gilead announced its audacious and unbelievably expensive $11 billion acquisition of Pharmasset (VRUS). A few days later, I sat down to reassess Martin's status. Did he still deserve the sting of this nomination? Or had he earned a reprieve, perhaps even a nod as a best biotech CEO candidate?

I decided that Martin still belongs here. The Pharmasset acquisition may transform Gilead into a hepatitis C drug powerhouse, or it might not. The Hep C treatment landscape is changing so quickly and competition is so intense, predicting which drugs may or not become future fixtures is nearly impossible.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ELN $0.00 0.00%
DNDN $0.06 -6.02%
AMRN $1.51 0.00%
GILD $103.53 0.00%
MNKD $6.52 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs